Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Form 4 overview: Immix Biopharma, Inc. (ticker: IMMX) filed a Form 4 reporting an open-market purchase by Chief Financial Officer and Director Gabriel S. Morris on 18 June 2025.
- Transaction details: Mr. Morris bought 2,225 common shares at a volume-weighted average price of $2.279 per share (code “P”).
- Direct ownership after transaction: 288,059 common shares held in his own name (ownership code “D”).
- Indirect ownership: 270,844 shares held through Alwaysraise LLC and 24,141 shares held through Alwaysraise Ventures I LP (ownership code “I”). For both entities, Mr. Morris disclaims beneficial ownership except to the extent of his pecuniary interest.
- No derivative securities were reported in Table II.
- The filing was electronically signed by Mr. Morris on 20 June 2025.
The Form 4 reflects Mr. Morris’ latest equity position and provides investors with an updated view of insider holdings as of 18 June 2025.